Blum Center Program: Understanding Osteoarthritis - Keeping Your Joints Moving

Why It Matters

Osteoarthritis drives billions in healthcare costs and lost productivity; novel GLP‑1 therapies could reshape treatment economics and market dynamics. Understanding these developments helps providers, payers, and investors anticipate shifts in care pathways and reimbursement.

Key Takeaways

• Osteoarthritis affects 32 million U.S. adults.
• GLP-1 drugs show anti-inflammatory potential.
• Early diagnosis reduces long‑term disability costs.
• Biologic injections dominate current market share.
• Medicare reimbursement policies influence treatment adoption.

Pulse Analysis

Osteoarthritis remains the most prevalent form of arthritis, impacting roughly 32 million adults in the United States and accounting for a sizable share of musculoskeletal disability. The condition drives billions of dollars in direct medical expenses and indirect costs such as lost productivity, making it a focal point for payers and health systems seeking cost‑containment strategies. As the population ages, incidence rates are projected to rise, prompting pharmaceutical companies and device manufacturers to expand research and development pipelines aimed at slowing disease progression and improving joint function.

Today's therapeutic arsenal for osteoarthritis blends pharmacologic, surgical, and lifestyle interventions. First‑line options include NSAIDs, intra‑articular corticosteroids, and physical‑therapy regimens, while disease‑modifying agents such as hyaluronic‑acid injections and emerging biologics capture a growing market share. Recent academic trials have highlighted glucagon‑like peptide‑1 (GLP‑1) receptor agonists—originally approved for diabetes and obesity—as potential modulators of joint inflammation and cartilage metabolism. If larger Phase III studies confirm efficacy, GLP‑1 agents could reshape prescribing patterns, opening new revenue streams for biotech firms and prompting insurers to reassess coverage frameworks.

The convergence of demographic pressure and therapeutic innovation positions osteoarthritis as a strategic investment theme. Venture capital and private‑equity funds are increasingly targeting companies developing disease‑modifying osteoarthritis drugs, especially those leveraging GLP‑1 chemistry or novel delivery platforms. Health systems, meanwhile, are piloting integrated care pathways that combine early imaging, digital monitoring, and personalized medication regimens to reduce joint replacement rates. Policymakers will likely monitor cost‑effectiveness data closely, as favorable outcomes could drive Medicare and private payer reimbursement reforms, accelerating market adoption of next‑generation treatments.

Original Description

Osteoarthritis is the most common form of arthritis and a leading cause of joint pain and disability. In this presentation from February 23, 2026, Avira Som, MD, explains what osteoarthritis is, common symptoms to watch for, and today’s treatment options. She also discusses emerging research on GLP-1 medications and their potential role in osteoarthritis care.

This session is a collaboration between the Maxwell & Eleanor Blum Patient and Family Learning Center and the Department of Rheumatology at Massachusetts General Hospital.